A study to examine the effects of Lactobacillus salivarius L55 intake on relief from eye and nasal discomfort.
- Conditions
- Healthy adults
- Registration Number
- JPRN-UMIN000035776
- Lead Sponsor
- IMEQRD Co., Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
1. Those who were categized into "severe" or "the most severe" according to the classification of allergic rhinitis based on severity of symptoms. 2. Those who have acute rhinitis, sinusitis, nasal polyp, hypertrophic rhinitis, and deviated septum. 3. Those who have bronchial asthma as a complication. 4. Those who have the serious disorders of the liver, heart, kidney, respiratory system, endocrine, and metabolism. 5. Those who currently receive or have previously received allergen immunotherapy. 6. Those who currently take some kind of medication for therapeutic purposes. 7. Those with a past and current medical history of drug or food allergy. 8. Those who ingest Lactobacillus preparations, Lactobacillus supplements, yogurts, foods for specified health use, and foods with function claims on a daily basis (however, at the time of submission of an informed consent document, those who can stop ingesting foods listed above during the study period are excluded). 9. Those who are currently pregnant or breastfeeding or those who desire a pregnancy during the study period. 10. Those who have experienced a feeling sick or health deterioration due to blood sampling. 11. Those who have diarrhea by dairy products and those who have lactose intolerance. 12. Those who participated in another clinical trial within one month before our screening test and those who took an active ingredient provided in the clinical trial. 13. Those who may undergo lifestyle changes (such as a long trip) during the study period. 14. Those who were determined by the principal investigator to be unsuitable for participation in this clinical trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Eye and nasal symptom questionnaire ,The Japanese Rhinoconjunctivitis Quality of Life Questionnaire version 2002 (JRQLQ No1)
- Secondary Outcome Measures
Name Time Method Assessment of the nasal cavity (mucosal swelling and mucosal color of the inferior turbinate, serous fluid volume, and characteristics of nasal discharge)